A carregar...

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Background: No standard chemotherapy is used as neoadjuvant therapy in triple negative breast cancer (TNBC). This study has compared carboplatin plus paclitaxel with commonly used epirubicin plus paclitaxel as neoadjuvant chemotherapy (NAC) in TNBC. Results: 91 patients with a median age of 47 years...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Zhang, Pin, Yin, Yi, Mo, Hongnan, Zhang, Bailin, Wang, Xiang, Li, Qing, Yuan, Peng, Wang, Jiayu, Zheng, Shan, Cai, Ruigang, Ma, Fei, Fan, Yin, Xu, Binghe
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312408/
https://ncbi.nlm.nih.gov/pubmed/27447966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10607
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!